Osteopontin expression and its relationship with prognostic factors in diffuse large b-cell lymphoma
Por:
Barranco G., Fernández E., Rivas S., Quezada R., Nava D., Aguilar J., García A., Astudillo H., Lome C., Ruiz E.
Publicada:
1 ene 2019
Categoría:
Hematology
Resumen:
The aim of this study is to explore the expression of osteopontin (OPN) and its relationship with prognostic factors and sur- vival in diffuse large B cell lymphoma (DLBCL). A tissue microarray was per- formed for immunohistochemical evalua- tion. Contingency tables were analyzed for trends; chi-square test was used to determine differences between groups. Univariate and multivariate Cox propor- tional hazards-regression analyses were performed to evaluate the impact of prog- nostic factors on survival. Expression of OPN was observed in 28%. It was different in non-germinal center DLBCL (P=0.04). The mean overall survival (OS) was lower in patients with positive OPN expression (19.762; CI 95% 14.269-25.255) it was not significant (P=0.123). It is not possible to establish a clear relationship between the expression by immunohistochemistry of osteopontin and a poor prognosis but it would be important to complement the analysis with other techniques as PCR or NGS that allow us to assess the influence of the isoforms and post-translational modifi- cations of OPN on the biological behavior of DLBCL. Our findings indicate that OPN expression could be associated with a more aggressive variant of lymphoma: Non-ger- minal center DLBCL. © the Author(s), 2019 Licensee PAGEPress, Italy.
Filiaciones:
Barranco G.:
Department of Hematology, General Hospital of Mexico, Mexico, Mexico
Fernández E.:
Translational Medicine, National Institute of Cancerology, Mexico, Mexico
Computational Genomics, National Institute of Genomic Medicine, Mexico, Mexico
Rivas S.:
Department of Hematology, National Institute of Cancerology, Mexico, Mexico
Quezada R.:
Department of Pathology, National Institute of Cancerology, Mexico, Mexico
Nava D.:
Department of Pathology, National Institute of Cancerology, Mexico, Mexico
Aguilar J.:
Department of Internal Medicine, National Institute of Cancerology, Mexico, Mexico
García A.:
Translational Medicine, National Institute of Cancerology, Mexico, Mexico
Astudillo H.:
Laboratory of Translational Cancer Research and Cellular Therapy, National Medical Center Siglo XXI, Mexico, Mexico
Lome C.:
Department of Pathology, National Institute of Cancerology, Mexico, Mexico
Ruiz E.:
Translational Medicine, National Institute of Cancerology, Mexico, Mexico
All Open Access, Gold
|